PKAN: Pantothenate Kinase-Associated Neurodegeneration

PKAN, short for pantothenate kinase-associated neurodegeneration, is a rare inherited disease that causes iron to build up in a specific region of the brain, progressively destroying a person’s ability to move, speak, and swallow. It is caused by mutations in the PANK2 gene, which provides instructions for an enzyme the body needs to make coenzyme A, a molecule involved in hundreds of metabolic reactions.¹ PKAN is the most common form of a broader group of conditions called neurodegeneration with brain iron accumulation (NBIA), accounting for roughly half of all NBIA cases. It typically strikes in childhood, though a later-onset form exists with a very different trajectory.

Why It Used to Have a Different Name

You may encounter older medical literature referring to PKAN as Hallervorden-Spatz disease or Hallervorden-Spatz syndrome. That name was deliberately retired. Julius Hallervorden, one of the two German neuropathologists who first described the condition in 1922, was deeply involved in the Nazi euthanasia program during World War II, personally collecting brains from victims for research.² When the responsible gene was identified in 2001, the medical community took the opportunity to rename the disease after the enzyme it affects, pantothenate kinase. If a doctor or older resource still uses the Hallervorden-Spatz label, they are talking about the same condition.

How PKAN Is Inherited

PKAN follows an autosomal recessive pattern, meaning a child must inherit a defective copy of the PANK2 gene from each parent to develop the disease.³ Parents who each carry one faulty copy are typically unaffected, because their one working copy produces enough functional enzyme. When two carriers have a child, there is a one-in-four chance the child will inherit both faulty copies and develop PKAN. More than 100 different PANK2 mutations have been identified, including point mutations and larger deletions of whole sections of the gene. Some of these deletions appear to be caused by repetitive DNA elements within the gene that can line up incorrectly when cells divide, snipping out critical stretches.⁴

What Goes Wrong Inside the Cell

The PANK2 enzyme sits inside mitochondria, the structures that generate energy for cells. Its job is to carry out the first step in building coenzyme A (CoA) from vitamin B5.⁵ CoA is essential for burning fats and sugars for energy, and the brain, which consumes a disproportionate share of the body’s energy, is especially vulnerable when CoA production falters. Without enough working pantothenate kinase 2, CoA levels drop in the central nervous system, and intermediary compounds that would normally be processed further, including cysteine-containing molecules, accumulate instead. Those cysteine compounds can bind iron, and the prevailing theory is that this trapping of iron in the globus pallidus, a small structure deep in the brain involved in movement control, drives the progressive damage.⁶ The iron generates damaging free radicals, which injure and kill neurons over time.

Classic Versus Atypical PKAN

Doctors generally divide PKAN into two forms based on when symptoms appear and how fast the disease progresses. Classic PKAN begins before age six and moves quickly. Children typically develop difficulty walking, muscle stiffness and involuntary twisting movements (dystonia), speech problems, and swallowing difficulties within the first few years. The classic form tends to involve more severe speech, swallowing, and visual problems, along with worse motor impairment.⁷ Many children with classic PKAN lose the ability to walk independently within about five years of symptom onset, and roughly three-quarters are unable to walk within ten years.⁸

Atypical PKAN starts later, often in the teens or twenties, and progresses more slowly. Its symptoms can look quite different from the childhood form. In a study of Korean adults with atypical PKAN, early symptoms included dystonia limited to one limb, features resembling Parkinson’s disease, jaw and mouth dystonia, and isolated freezing of gait, where a person suddenly cannot initiate or continue a step. People who developed symptoms later in life were more likely to present with parkinsonism and gait freezing rather than the widespread dystonia seen in the classic form.⁹ The prognosis diverges sharply between the two forms. Among people with classical PKAN, the probability of still walking at nine years of disease was about 43%, dropping to about 28% at fifteen years. For atypical PKAN, the chance of preserving independent walking was roughly 89% at seven years and 85% at nine years.¹⁰

The Eye of the Tiger Sign

PKAN has one of the most recognizable findings in all of neuroimaging. On a brain MRI, a T2-weighted scan of the globus pallidus shows a dark region surrounding a bright central spot, creating a pattern that looks remarkably like a tiger’s eye. The dark rim reflects massive iron deposits, while the bright center corresponds to tissue damage and a type of scarring called gliosis.¹¹ For years this pattern was considered virtually diagnostic for PKAN, and finding it on a scan often prompted genetic testing. However, it is not unique to PKAN. The same sign has occasionally appeared in adults with other conditions, so while it remains a strong clue, it is not definitive on its own.¹²

Newer imaging techniques can measure the actual amount of iron in specific brain regions rather than just showing a pattern. Quantitative susceptibility mapping (QSM) has revealed that iron levels are elevated not only in the globus pallidus but also in the substantia nigra, another deep brain structure involved in movement. On QSM maps the pattern can actually appear inverted compared to the classic MRI, with the iron-heavy areas showing up bright instead of dark.¹³ These quantitative methods are becoming more important for tracking whether treatments are actually reducing brain iron over time.

Vision Problems and the Retina

Movement difficulties dominate the clinical picture, but PKAN also affects the eyes. The retina, which is technically an extension of the central nervous system, depends on the same mitochondrial CoA pathways that fail in PKAN. Mouse models lacking the Pank2 gene develop progressive loss of photoreceptor cells, the light-sensing neurons in the retina. One study found that the layer of the retina containing photoreceptors was thinner by an average of 10 micrometers across the period studied, with corresponding drops in electrical responses to light.¹⁴ Earlier work in these knockout mice showed the same pattern using electrical recordings and microscopy, along with reduced pupil constriction in response to light.¹⁵ In people with PKAN, visual decline is a recognized feature, particularly in classic cases, and retinal degeneration (specifically pigmentary retinopathy) is one of the features clinicians look for during evaluation. This is worth knowing because vision changes in a child with movement problems can be an early diagnostic clue.

Managing Symptoms Today

There is currently no treatment that reverses PKAN, so management focuses on slowing progression and easing day-to-day symptoms. The main targets are dystonia, spasticity, and the cascade of problems they cause, from difficulty eating to painful muscle spasms.

Oral medications like baclofen, which relaxes muscles, and injections of botulinum toxin into the most severely affected muscles can improve motor symptoms and make daily care easier.¹⁶ Botulinum toxin is especially useful for targeting specific muscle groups, like those controlling jaw clenching or neck posture, without sedating the whole body. For people whose dystonia does not respond adequately to medications, deep brain stimulation (DBS) is an option. In DBS, electrodes are surgically placed in the globus pallidus and connected to a small pulse generator, delivering electrical signals that modulate the faulty circuits.

A Korean study followed PKAN patients who received bilateral DBS for refractory dystonia over several years. The dystonia scores improved by about 41% at two to three years and about 31% at five to six years, suggesting the benefit persists but gradually diminishes. What is striking, though, is that even while dystonia ratings remained better than before surgery, patients’ subjective disability scores worsened from about two to three years onward, mainly because of worsening eating and feeding difficulties.¹⁷ The disease continues to progress even when dystonia is partially controlled, and the non-motor aspects, like swallowing, can worsen independently. This gap between measurable movement improvement and real-world disability is something families should understand going into DBS decisions.

Iron Chelation With Deferiprone

Since iron accumulation drives much of the brain damage, removing that iron is an obvious therapeutic strategy. Deferiprone is an iron-chelating drug, originally developed for conditions like thalassemia where iron overload is a major problem, that has the advantage of crossing the blood-brain barrier. Several pilot trials have tested it in PKAN.

In an early pilot study, deferiprone reduced iron accumulation in the globus pallidus on MRI and produced mild to moderate motor improvement in some patients with NBIA, including those with PKAN.¹⁸ A four-year follow-up study found that motor symptoms stabilized in five out of six patients, and MRI confirmed a significant reduction in iron content in the globus pallidus.¹⁹ Another small trial reported that deferiprone reduced the iron load in the globus pallidus of all enrolled patients, with clinical improvement visible in most during the first twelve months.²⁰

These results are encouraging but should be interpreted carefully. All of these studies were small, open-label trials without placebo controls. Larger randomized trials have been conducted since, and the picture has become more complicated. A prominent randomized trial (TIRCON2012) did not demonstrate a significant clinical benefit despite evidence of iron reduction on imaging. The disconnect between clearing iron and improving symptoms raises a difficult question: by the time iron has been accumulating for years, has irreversible neuronal damage already occurred? Or is iron accumulation more of a downstream marker than the primary driver of disease? Researchers are still working this out, and deferiprone remains under investigation rather than a standard-of-care treatment.

Therapies That Target the Root Cause

Rather than mopping up iron after it accumulates, a more elegant strategy would be to fix the metabolic defect that causes the accumulation in the first place. Since PKAN results from insufficient coenzyme A production, several groups have tried to supply the missing ingredient directly.

Fosmetpantotenate (also called RE-024) was designed as a prodrug that delivers phosphopantothenic acid, the product of the reaction that the faulty PANK2 enzyme can no longer perform. In lab studies, it restored CoA levels in neuroblastoma cells where PANK2 had been silenced, and it crossed a blood-brain barrier model, suggesting it could reach the brain.²¹ Unfortunately, fosmetpantotenate did not show clinical benefit in its Phase 3 trial and its development was discontinued. The failure was a significant setback for the PKAN community but also motivated work on next-generation compounds.

Researchers have since developed cyclic phosphopantothenic acid prodrugs, which use a different chemical strategy to deliver the same missing metabolite to the brain. These compounds aim to be more stable and more efficiently absorbed than fosmetpantotenate.²² Other approaches under exploration include gene therapy, which would introduce a functional copy of the PANK2 gene directly into brain cells, and small-molecule activators of the other pantothenate kinase enzymes (PANK1, PANK3) that exist outside the mitochondria and might partially compensate for the loss of PANK2. These are still in preclinical stages, but the variety of approaches reflects a field that is actively searching for solutions rather than stuck on a single failed strategy.

What Animal Models Have Revealed

One of the frustrations of PKAN research is that the most commonly used mouse model does not fully recapitulate the human disease. Mice engineered to lack the Pank2 gene develop retinal degeneration and male infertility but, puzzlingly, do not show the severe movement disorder or brain iron accumulation that defines the human condition.²³ At the cellular level, however, neurons from these mice do show the expected problems: swollen mitochondria, abnormal membrane potential, and defective energy production. The brain pathology is there at a microscopic level even when it doesn’t translate into visible neurological symptoms in the mouse.

A different mouse model, in which brain CoA was depleted more aggressively, produced a closer match to human symptoms. These mice showed reduced locomotion, abnormal gait, and forelimb flexing that worsened over time. Gene expression analysis of their brains revealed patterns consistent with oxygen and glucose deprivation, essentially a brain starved of the metabolic fuel it needs.²⁴ This model has been more useful for testing potential therapies, because it produces measurable neurological decline that can be tracked over time. The gap between the two models underscores how much remains unknown about why CoA deficiency damages the human globus pallidus so selectively, and why mice seem partly protected from the same fate.

Living With PKAN and Finding Support

Because PKAN is rare, many families receive the diagnosis after a long and uncertain journey through multiple specialists. A survey of patients and caregivers found that the burden of the disease extends well beyond movement problems. Caregivers of people with classic PKAN reported heavy demands around feeding, communication, and daily personal care, while people with atypical PKAN often dealt with the psychosocial weight of a progressive diagnosis in adolescence or young adulthood.²⁵ Organizations like the NBIA Disorders Association and the NBIA Alliance connect families with each other and with researchers running clinical trials. Genetic counseling is important for extended family members who may unknowingly carry one copy of a PANK2 mutation, especially if they are considering having children. Because the disease is autosomal recessive, siblings of an affected child each have a two-in-three chance of being carriers even if they show no symptoms.

For families already managing PKAN, a multidisciplinary care team is the practical reality. Neurologists manage the movement disorder, ophthalmologists monitor the retina, speech therapists work on swallowing and communication, and physiatrists or physical therapists help maintain function as long as possible. Nutritional support becomes increasingly important as swallowing deteriorates, sometimes requiring a feeding tube. No single specialist can manage the disease alone, and coordinating care across these disciplines, often at centers that rarely see PKAN, is one of the biggest practical challenges families face.